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Abstract
Background: There has been a noticeable annual increase in the number of children coming to Italy for medical
treatment, just like it has happened in the rest of the European Union. In Italy, the assistance to children suffering
from cancer is assured by the current network of 54 centres members of the Italian Association of Paediatric
Haematology and Oncology (AIEOP), which has kept records of all demographic and clinical data in the database
of Mod.1.01 Registry since 1989.
Methods: We used the information stored in the already mentioned database to assess the impact of immigration
of foreign children with cancer on centres’ activity, with the scope of drawing a map of the assistance to these
cases.
Results: Out of 14,738 cases recorded by all centres in the period from 1999 to 2008, 92.2% were born and
resident in Italy, 4.1% (608) were born abroad and living abroad and 3.7% (538) were born abroad and living in
Italy. Foreign children cases have increased over the years from 2.5% in 1999 to. 8.1% in 2008.
Most immigrant children came from Europe (65.7%), whereas patients who came from America, Asia and Oceania
amounted to 13.2%, 10.1%, 0.2%, respectively. The immigrant survival rate was lower compared to that of children
who were born in Italy. This is especially true for acute lymphoblastic leukaemia patients entered an AIEOP
protocol, who showed a 10-years survival rate of 71.0% vs. 80.7% (p < 0.001) for immigrants and patients born in
Italy, respectively.
Conclusions: Children and adolescents are an increasingly important part of the immigration phenomenon, which
occurs in many parts of the world. In Italy the vast majority of children affected by malignancies are treated in
AIEOP centres. Since immigrant children are predominantly treated in northern Italy, these centres have developed
a special expertise in treating immigrant patients, which is certainly very useful for the entire AIEOP network.
Background
Although immigration in Italy is considered as a recent
occurrence, our country has been traversed for centuries
by different migration flows, which have always influ-
enced our social and cultural life, and which is visible
by the numerous ethnic and linguistic minorities still
present today.
In the modern era, the phenomenon of immigration in
Italy started around the 70s, but only in the early 80’si t
assumed such dimensions, so as to push the enacting of
the first law for immigration regulation in 1986 [1]. In
the early 90’s, foreigners living in Italy were estimated in
more than half a million, with less than 5% being chil-
dren. According to the latest report of the Italian
National Institute of Statistics (Istat), there were approxi-
mately 4 million foreigners living in Italy in 2008, and
they represented 6.5% of the total population, with more
than 20% (or 863,453) being children, over half of whom
were born foreigners in our country [2].
However, in Italy the overall share of foreigners is
lower than that of other European countries with older
immigration history, ranking only above Finland and
Portugal. Those numbers change considerably if taken
into consideration only northern Italy, which become
comparable to France’s numbers [3].
Most foreigners living in Italy, according to the Istat
report of 2009, come from Europe (53.6%), whereas
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Foreign minor and immigrant
According to the Italian law, a foreigner is a non European
Union (EU) citizen.
As reported in the Laws 268/1998 and 394/1999, a
person who was born in Italy of non-citizen parents is
only able to acquire the Italian citizenship after reaching
the legal majority. Indeed, Italian citizenship is granted
automatically only to children of Italian citizens [4,5].
If not born in Italy, foreign minors may enter our coun-
try to be reunited with a parent (or guardian), in response
to a request for asylum, to be adopted, to study, to pursue
professional sports, in solidarity programs, or for health
reasons.
The entry in Italy of a foreign citizen for health reasons
requires a request of a special visa, provided that the for-
eign national can financially support the treatment, indivi-
dually or with the support of an association acknowledged
by regional government, and after the approval from the
chosen health facility.
However, most cases of foreign child treatment fall
under the humanitarian aid provided by the Ministry of
Health in cooperation with the Ministry of Foreign Affairs,
which ensures full coverage of health services, in recipro-
cal agreements on health care [6,7]. Another source of
financial support is represented by humanitarian programs
adopted by the regions, authorizing local health authorities
to provide highly specialized services for foreigners from
countries that lack the necessary skills.
Moreover, even children who entered illegally in our
country have all fundamental rights (including health
care) guaranteed, in compliance with the New York
Convention on the Rights of the Child of 1989, and as
stipulated by the Law 189/2002 [8,9].
Health care for foreign children with cancer: the AIEOP
centres and the Registry Mod.1.01
Providing health care to foreign children put to a severe
test the organizational abilities of our health care facil-
ities, since it requires a whole new level of cultural and
social awareness imposed by the continuous arising of
the multicultural immigration.
In Italy, the assistance of all children with cancer is
assured by the current network of 54 centres of the Ita-
lian Association of Paediatric Haematology and Oncol-
ogy (AIEOP).
Since 1989, all data has been recorded in the database
of AIEOP Mod.1.01 Registry [10,11]. This allows the
monitoring of admissions, the evaluation of their biolo-
gical and demographic characteristics and some indica-
tors of quality of care, such as adherence to official
protocols and survival.
Therefore, we wanted to use the database of Mod.1.01
Registry to assess the impact of immigration of foreign
children with cancer on AIEOP centres’ activity, in
order to draw a map of assistance to these cases.
Patients and methods
Setting and sample
To this purpose, we used information on all registered
cancer cases in the database of Mod.1.01 Registry from
AIEOP centres, with age of less than 18 years old at diag-
nosis, from 1999 (the year in which began the systematic
collection of the foreign country of birth and residence)
to 2008.
We prefer the definition of immigrant to the definition
of foreigner, since the former allows assessing the phe-
nomenon more completely, as it also includes patients
from EU countries whereas the second is simplistic and
incomplete (as a synonym for non-EU citizen).
Therefore, the information relating to immigrant chil-
dren (foreign-born and resident in Italy or abroad), was
compared to that of cases born and resident in Italy.
The cases born in Italy and living abroad were excluded
from the study, because they were considered migrants.
Statistical analysis
Data were analyzed as of December 31, 2009. All data
were stored in a central database (Mod.1.01 Registry),
and were processed at the AIEOP Operation Office [12].
Patients’ characteristics, such as recruitment by year, type
of disease, age at diagnosis, geographical area of origin,
distribution on the Italian territory, and treatment centre,
were analyzed and compared, when appropriate, using
the c
2 or Fisher’s exact test in the case of discrete vari-
ables, or the Mann-Whitney test in the case of continu-
ous variables. 95% Confidence Interval (CI) of mean or
percentage were reported in case of statistically signifi-
cant difference.
Overall survival (OS) was computed from the date of
diagnosis to the date of death from any cause, or the last
date of contact, if still alive. Survival distributions were
estimated using the method of Kaplan and Meier, and
the log-rank test was used to examine differences among
subgroups [13]. Results were expressed as cumulative
probability (%) and standard error (SE).
Since the follow-up numbers were based only on con-
tact to AIEOP centers - available only in 47% of all cases,
being 43% immigrants and 47% born in Italy, - and not
supplemented by active research, we chose to report OS
only for cases affected by acute lymphoblastic leukaemia
(ALL) entered an AIEOP protocol, as the follow-up data
was available for 93% of ALL cases. Unfortunately, these
follow-up data were missing from 35% to 75% of cases
affected by other disease and for the majority of cases
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leave such cases out of our study.
Multivariate Cox proportional hazards analysis was
used to explore some basic factors potentially associated
with survival in ALL treaded with an AIEOP protocol:
patient’s birth place (immigrants vs. born in Italy),
patients’ gender (male vs. female), age at diagnosis (> 14
years vs. ≤ 14 years) and risk group (high vs. no-high)
[14].
Adequacy of data to the proportional hazard assump-
tions of the Cox model was verified by plotting the loga-
rithm of the cumulative hazard function against the
logarithm of survival time, checking for parallelism.
All P values are 2-sided and values less than 0.05 were
considered statistically significant.
Statistical analysis was carried out using the Stata sta-
tistical package, version 7.0 [15].
Results
For 14,738 cases out of 14,868 (99.1%) recorded by all
AIEOP centres in the period from 1999 to 2008 from,
in which the place of birth and residence were known,
excluding 27 cases born in Italy but emigrated abroad,
92.2% (13,592 cases) were born and resident in Italy,
while 4.1% (608) were born and living abroad, and 3.7%
(538) were born abroad and living in Italy. Excluding
293 cases that were born in one of the 27 EU countries,
non-EU amounted to 5.8% of the cases.
The admission of immigrant children has gradually
and steadily increased over the years, from 31 cases,
2.5% of the total in 1999 to 130 cases, 8.1% of the total
in 2008, with an average of about 115 cases/year, while
cases born in Italy amounted to about 1,360 cases/year
(Figure 1).
Foreign children amount to 9.3% of cases with leukae-
mia and lymphoma, and 6.3% of cases with solid
tumours. The number of immigrant cases with leukae-
mia and lymphoma increased over the years from 2.8%
in 1999 to 9.4% in 2008, while solid tumours increased
from 2.1% to 7.1% in the same period (Figure 1).
Most immigrant children seeking treatment come
from Europe (65.7%); 40.1% from outside the EU, of
which the majority from Albania (21.5%), from the
countries of the former Yugoslavia (10.9%), Ukraine
(4.3%) and Russia (1.0%) and 25.6% from EU countries
such as Romania (16.8%), Germany (2.1%) and Greece
(1.7%), while only 6 cases are born and resident in the
Republic of San Marino.
The 13.2% of immigrants in need of medical care
came from the Americas, led by Venezuela (4%), fol-
lowed by Ecuador (1.9%); 10.8% from Africa, mainly
from Morocco (3.8%) and Libya (1.6%); 10.1% from
Asia, especially from Iraq (1.4%), and only 2 cases from
Oceania (0.2%) (Figure 2).
The 59.4% of immigrant children cases were being
treated in AIEOP centres of northern Italy, 32.6% in the
centres of central Italy, while only 8% in southern Italy
centres, whereas for cases born in Italy, the distribution
was: 54.1%, 22.5% and 23.4%, respectively (Figure 3).
The male/female ratio was slightly higher for immi-
grants than for cases of patients who were born in Italy
(1.4 vs. 1.3). It was also true regarding the age: 8.0 (95%
CI 7.7-8.2) years old vs. 6.7 (95% CI 6.6-6.8) years old in
those cases of patients born in Italy (p < 0.001), which
resulted in a greater proportion of adolescents (> 10
years) among immigrants (41% vs. 32% of patients born
in Italy).
About 59% (95% CI 56-62) of immigrant cases con-
sisted of leukaemia and lymphoma vs. 48% (95% CI 47-
49) of cases born in Italy (p < 0.001).
The frequency of leukaemia was greater for immi-
grants (46.9% vs. 33.4%), in which prevails ALL, but also
with high relative frequency of acute non-lymphoblastic
leukaemia and other leukaemia, mainly chronic myeloid
leukaemia, of which immigrant children represented
over 15% of all cases of these two forms registered by
AIEOP centres. The frequency of lymphomas was rather
similar in both groups (Table 1).
Approximately 41% (95% CI 38-44) of immigrant
cases consisted of solid tumours vs. 52% (95% CI 51-53)
of cases from patients born in Italy (p < 0.001). The
relative frequency of solid tumours was lower in immi-
grants, except those of retinoblastoma (3.4% vs. 2.3%),
where immigrant children represented over 10% of all
cases recorded by the AIEOP centres with this type of
cancer (Table 1).
It is important to highlight that the relative frequency
of bone tumours in immigrants was two times higher
than that of patients born in Italy, especially osteosar-
coma, which as many as 17% of all cases are immigrants
(Table 1). Most of these patients resulted born in Roma-
nia (31.3%), Albania (27.1%) and Libya (10.4%).
Finally, low was the incidence of germ cell tumours in
immigrants, while the relative frequency of carcinomas
was similar in both groups (Table 1).
The number of immigrant cases treated with AIEOP
protocols was significantly lower than that of cases of
patients born in Italy: 56% (95% CI 53-59) vs. 73% (95%
CI 72-74), p < 0.001. Same result if we consider the
cases with leukaemia and lymphoma: 60% (95% CI 56-
64) vs. 90% (95% CI 89-91), p < 0.001, or solid tumours:
51% (95% CI 46-55) vs. 57% (95% CI 56-58), p < 0.01.
Only 6,896 cases out of 14,738 (46.8%) resulted evalu-
able for survival analysis: 5,422 were alive (354 immi-
grants and 5,068 born in Italy) and 1,474 were deceased
(168 immigrants and 1,306 born in Italy), while the
number of lost to follow-up were 56 (0.8%): 7 immi-
grants and 49 born in Italy.
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groups (48 months for immigrants vs. 52 months for
born in Italy) the survival of immigrant cases was signif-
icantly lower (p < 0.001) compared to that of patients
who were born in Italy: 10-years OS: 53.2% (SE 4.4) vs.
70.8% (SE 1.3).
In ALL patients treated by an AIEOP protocol, after a
median observation time similar in both groups
 
 
 
a 
b 
c 
Figure 1 Overall accrual by year (a), for leukaemia and lymphoma (b) and solid tumours (c).
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Figure 2 Migration flows by country of origin.
Figure 3 Percentage of immigrant cases by geographical area and region of treatment.
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Italy) the survival of immigrant cases was significantly
lower (p < 0.001) compared to patients who were born
in Italy: 10-years OS: 71.0% (SE 4.1) vs. 80.7% (SE 3.0)
(Figure 4).
Always in this group of patients, analysis of prognostic
factors, also underscored that being an immigrant was a
negative and independent prognostic factor with risk of
death of more than 1.5 times compared to cases of
patients who were born in Italy, likewise high risk
group, male and age > 14 years (Table 2).
Discussion
Migration has always involved an uncountable number
of motivations and reasons, and it has marked the his-
tory of mankind over the centuries. Moreover, it is no
surprise that nowadays children and adolescents are
increasingly being perceived as an important part of the
immigration phenomenon.
The entry of several Eastern European countries into
the EU, and today’s rapid dissemination of information,
have produced in the last ten years an acute increase in
families from developing countries coming to Western
European countries seeking the best possible treatment
for children suffering from cancer, and Italy is no
exception.
The analysis of the database of Mod.1.01 Registry
showed that immigrants represented about 8% of all
cases registered by AIEOP centres, totalling approxi-
mately 115 cases/year (85 from non-EU countries).
The geographical origin of immigrant cases was similar,
though not identical, to that reported by the Istat.
Among the foreign cases from European countries
admitted in AIEOP centres, for example, despite the Istat
reporting a rapid increase in the Romanian community
(currently the main foreign community in our country),
Albanians still exceeded the Romanians in the AIEOP
statistics. Among the Asian nationalities, Iraqis were
more numerous than the Chinese, while the Venezuelans
were more than the Ecuadorians among American
nationalities. Finally, patients from Morocco were con-
firmed to be the most represented among the Africans,
as also reported by the Istat [2]. However, it is possible
that the high number of cases from Iraq and Venezuela
were largely influenced by programs of health coopera-
tion between Italy - through the Ministry of Health or
some Italian regions, - and those countries, in accordance
with the provisions of the guidelines of the Italian devel-
opment cooperation [16,17].
We have already mentioned how immigrant children
are accepted predominantly (59%) by AIEOP centres of
northern Italy, the same as for cases of patients who
were born in Italy [18].
At the same time, AIEOP centres of central Italy
accepted 33% of immigrants and the proportion of these
immigrant cases on overall treated cases was consider-
ably high (15% in Tuscany and Umbria), even if the
higher proportion was found in the northern region of
Friuli (20%).
The centres of these regions (northern and central
Italy) have therefore developed special expertise and
skills in treating immigrant patients, which are certainly
very useful for the AIEOP network.
Ultimately, as opposed to the cases of patients who
were born in Italy, we had seen a higher number of males
in immigrant children, a higher age at diagnosis, and a
greater and significant share of leukaemia and lymphoma,
especially those of more severe prognosis types. That was
probably due to the fact that most of the cases that came
to Italy were only to perform haematopoietic stem cell
transplantation (HSCT), which may explain in part the
lower survival, together with the reduced share of cases
that were treated with AIEOP protocols.
Table 1 Distribution of cases by diagnosis
Diagnosis Immigrants Born in Italy Total
N.cases % N.cases % N.cases %
Leukaemia 537 46.9 4,536 33.4 5,073 34.4
ALL 347 30.3 3,593 26.4 3,940 26.7
AML 132 11.5 710 5.2 842 5.7
OL 58 5.1 233 1.7 291 2.0
Lymphoma 136 11.9 2,008 14.8 2,144 14.5
HL 49 4.3 1,047 7.7 1,096 7.4
NHL 87 7.6 946 7.0 1,033 7.0
CNS tumours 119 10.4 2,119 15.6 2,238 15.2
SNS tumours 57 5.0 1,093 8.0 1,150 7.8
NB 55 4.8 1,061 7.8 1,116 7.6
RTB 39 3.4 308 2.3 347 2.4
Kidney tumours 26 2.3 621 4.6 647 4.4
WT 25 2.2 540 4.0 565 3.8
Liver tumours 11 1.0 128 0.9 139 0.9
Bone tumours 93 8.1 582 4.3 675 4.6
Osteorarcoma 48 4.2 231 1.7 279 1.9
ES 45 3.9 327 2.4 372 2.5
STS 68 5.9 885 6.5 953 6.5
RMS 41 3.6 438 3.2 479 3.3
GCT 10 0.9 382 2.8 392 2.7
Carcinomas 16 1.4 174 1.3 190 1.3
Thyroid 2 0.2 36 0.3 38 0.3
Melanoma 0 - 34 0.3 34 0.2
Other tumours 34 3.0 756 5.6 790 5.4
Total 1,146 100 13,592 100 14,738 100
Legend: ALL, acute lymphoblastic leukaemia; AML, acute myeloblastic
leukaemia; OL, other leukaemia; HL, Hodgkin’s lymphoma; NHL, non-Hodgkin’s
lymphoma; CNS, central nervous system; SNS, sympathetic nervous system;
NB, neuroblastoma; RTB, retinoblastoma; WT, Wilm’s tumour; ES, Ewing’s
sarcoma; STS, soft tissue sarcoma; RMS, rabdomiosarcoma; GCT, germinal cells
tumour.
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percentage of immigrants affected and treated by retino-
blastoma or osteosarcoma, even if not that significant,
were probably due to the high specialization needed to
treat this disease, which probably may have led the
immigrants to contact some specialized AIEOP center
with international know-how.
There are several possible causes for recruitment failure
in AIEOP protocols, and they can be rather difficult to
explain: on one hand, 23% of these cases had their
diagnosis made in the country of origin, and they were
pre-treated with other protocols, which undermines
AIEOP protocols eligibility. On the other hand, cases may
be in a stage of disease that only allows individualized
therapy or HSCT. In fact, although 31% of immigrants
were submitted to HSCT, in 17% of these cases, the
patient arrived in Italy just to perform transplantation.
We found a significant lower OS in immigrants com-
pared to the cases of patients who were born in Italy,
but follow-up data was available only for 47% of all
cases, which could definitely mislead the final statistics.
Therefore, we decided to consider only the group of
ALL cases entered an AIEOP protocol, in which follow-
up was updated for all cases, and which would conse-
quently be a more reliable source of data. Using such
criteria, the OS was similar to that reported by AIEOP
in last long-term results report on study 95: 10-years
OS 80.3% (1.7) vs. 82.4% (SE 1.0) [19].
The significant difference in terms of OS reported
between immigrants with ALL compared to ALL in
patients who were born in Italy was probably due in part
to a higher and significant rate of high risk cases in immi-
grants (17.9%, 95% CI 12-24, vs. 2.5%, 95% CI 2-3, p <
0.001) and in part to other yet undefined factors. In
 
Figure 4 Overall survival for acute lymphoblastic leukaemia cases entered an AIEOP protocol.
Table 2 Survival: multivariate analysis in acute
lymphoblastic leukaemia cases entered an AIEOP
protocol
Variables Hazard Ratio
(95% Confidence Interval)
p
Age > 14 years vs. Age ≤ 14 years 2.20
(1.51 - 3.21)
0.000
Male vs. Female 1.49
(1.20 - 1.86)
0.000
High risk vs. no-High risk 2.01
(1.28 - 3.16)
0.002
Immigrants vs. Born in Italy 1.70
(1.16 - 2.50)
0.007
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and independent role affecting OS, such as high risk
group, age > 14 years and male gender, but this need
more detailed studies including all known prognostic fac-
tors in the case of ALL.
Conclusions
Undeniably, this analysis has highlighted some limitations
of the Mod.1.01 Registry, such as the fact that it was not
possible to identify children born in Italy to foreign
parents.
Another limitation was the difficulty in obtaining a
homogeneous follow-up of all cases, but for patients
entered in some AIEOP protocol, such as for ALL,
w h i c hd a t ab a s ei sl i n k e dt oM o d . 1 . 0 1R e g i s t r yd a t a
base. Despite these limitations, survival analysis has
demonstrated the poorer prognosis for immigrants chil-
dren compared to patients who were born in Italy,
which could depend on some known (i.e. higher risk
cases) and unknown factors that could be investigated
with “ad hoc” studies.
Nonetheless, Mod.1.01 Registry has demonstrated its
effectiveness as an instrument to measure the phenom-
e n o no fi m m i g r a t i o no ff o r e i g n - b o r nc h i l d r e ns u f f e r i n g
from cancer, who referred to the network of AIEOP
centres, and also to identify the new needs of the pae-
diatric population with cancer in Italy, which tends to
be increasingly more multiracial in the near future.
Indeed, cultural, religious, and social differences dee-
ply affect the way patients and their families face the
disease - besides the limitations on communication due
to linguistic barriers, - and as a result, it is currently
required organizational and administrative improve-
ments on how to assist foreign patients with cancer.
In addition, the diverse origin of those patients reports
a greater need to provide adequate documentation to the
families coming to the AIEOP centres, information con-
cerning the ward’s organization and rules, and informed
consent in the patients’ languages, as well as the need for
cultural mediators to communicate with family members
not only at critical moments, but often daily, during regu-
lar therapeutic procedures.
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